<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>14 CLINICAL STUDIES<BR><BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.1 Study 1: Placebo Controlled Study in CTCL (Stage Ia to III) Patients<BR><BR>                     <BR>                        The safety and efficacy of Ontak were evaluated in a randomized, double-blind, placebo-controlled, 3-arm trial in patients with Stage Ia to III CD25(+) CTCL. Eligible patients were required to have expression of CD25 on ≥ 20% of biopsied malignant cells by immunohistochemistry [see Warnings and Precautions (5.4)]. Patients were randomized to receive 0, 9 or 18 mcg/kg/day Ontak via intravenous infusion days 1-5 of each 21-day cycle, for up to 8 cycles. Randomization was stratified by disease stage (≤IIa vs. ≥IIb). The main efficacy outcome was objective response rate (ORR), using a Weighted Skin Severity Index, in conjunction with assessment of lymph node involvement and percentage of abnormal blood lymphocytes. A total of 144 patients were randomized: 44 patients to placebo, 45 patients to 9 mcg/kg/day Ontak and 55 patients to 18 mcg/kg/day Ontak. Randomization for the study was carried out at 1:1:1 for the first 73 patients, 4:1:4 for the next 31 patients, and 1:4:4 for the remaining 40 patients. The median age of patients was 59 years (range 23 to 84 years); 34% were ≥ 65 years. Fifty-five percent were men and 86% were Caucasian. Sixty-seven percent had early stage disease (≤ IIa). Patients had received a median of 2 anti-CTCL therapies (range 0 to 6) prior to study entry. Results for objective response rate (ORR) and progression-free survival (PFS) are shown in the table below.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>Table 2: Efficacy Results in Study&#160;1<BR></caption><BR>                           <col width="31%" align="left"/><BR>                           <col width="23%" align="center"/><BR>                           <col width="23%" align="center"/><BR>                           <col width="23%" align="center"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="4" align="left"><BR>                                    <sup>a</sup> Adjusted for disease stage and changes in randomization ratios.<br/><BR>                                    <sup>b</sup> Logistic regression model adjusting for disease stage and changes in randomization ratios over the course of the study; comparisons relative to placebo.<br/><BR>                                    <sup>c</sup> Cox regression analysis stratified by randomization ratio and adjusted for disease stage; comparisons relative to placebo.<BR></td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Efficacy Endpoint<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Ontak<br/>18&#160;mcg/kg/day<br/>(N=55)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Ontak<br/>9&#160;mcg/kg/day<br/>(N=45)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Placebo<br/>(N=44)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>ORR %<sup>a</sup><BR>                                 </td><BR>                                 <td styleCode="Lrule Rrule"><BR>46%<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>37%<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>15%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;p-value<sup>b</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>p=0.002<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>p=0.03<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>--<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Median Response Duration<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>220&#160;days<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>277&#160;days<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>81&#160;days<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>PFS<sup>c</sup><BR>                                 </td><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>&#160;&#160;&#160;Hazard ratio<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>0.27<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>0.42<BR></td><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>&#160;&#160;&#160;(95% CI)<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>(0.14, 0.54)<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>(0.20, 0.86)<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>--<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;p-value<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>p=0.0002<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>p=0.02<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.2 Study 2: Dose Evaluation Study in CTCL (Stage IIb to IVa) Patients<BR><BR>                     <BR>                        A randomized, double-blind study was conducted to evaluate doses of 9 or 18 mcg/kg/day in 71 patients with recurrent or persistent, Stage Ib to IVa CTCL. Entry to this study required demonstration of CD25 expression on at least 20% of the cells in any relevant tumor tissue sample (skin biopsy) or circulating cells. Tumor biopsies were not evaluated for expression of other IL-2 receptor subunit components (CD122/CD132). Ontak was administered as an IV infusion daily for 5 days every 3 weeks. Patients received a median of 6 courses of Ontak therapy (range 1 to 11). The study population had received a median of 5 prior therapies (range 1 to 12) with 63% of patients entering the trial with Stage IIb or more advanced stage disease. The median age of patients was 64 years (range 26 to 91 years); 49% were ≥ 65 years. Fifty-two percent were men and 75% were Caucasian.<BR>                        Overall, 30% (95% CI: 18-41%) of patients treated with Ontak experienced an objective tumor response (50% reduction in tumor burden which was sustained for ≥6 weeks; Table 3). Seven patients (10%) achieved a complete response and 14 patients (20%) achieved a partial response. The overall median duration of response, measured from first day of response, was 4 months with a median duration for complete response of 9 months and for partial response of 4 months.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>Table 3: Efficacy Results in Study&#160;2<BR></caption><BR>                           <col width="44%" align="left"/><BR>                           <col width="28%" align="center"/><BR>                           <col width="28%" align="center"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule" align="center"><BR>Clinical Response<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>9&#160;mcg/kg/day<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>18&#160;mcg/kg/day<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>Complete Response<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>9% (3/35)<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>11% (4/36)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;95% Confidence Interval<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(2%, 23%)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(3%, 26%)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>Partial Response<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>14% (5/35)<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>25% (9/36)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;95% Confidence Interval<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(9%, 30%)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(12%, 42%)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>Overall Response<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>23% (8/35)<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>36% (13/36)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;95% Confidence Interval<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(10%, 40%)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(21%, 54%)<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>